A new way of treating serious asthma and chronic obstructive pulmonary disease (COPD) attacks could be a “game changer” and its first leap in treatment in 50 years, researchers say. According ...

Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here. Lower blood eosinophil counts ...

At the time of the attack, the treatment consists of an injection of benralizumab, in a high dose. As reported by the media ...

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...